Stockholders' Equity (Tables)
|
12 Months Ended |
Dec. 31, 2022 |
Equity [Abstract] |
|
Summary of Share-Based Compensation Expense |
The following table sets forth share-based compensation expense included in the consolidated statements of operations:
|
|
|
|
|
|
|
|
|
|
|
|
|
Years Ended December 31, |
|
(in thousands) |
|
2022 |
|
2021 |
Cost of revenue |
$ |
63 |
|
|
$ |
30 |
|
Research and development |
1,060 |
|
|
464 |
|
Sales and marketing |
809 |
|
|
351 |
|
General and administrative |
2,194 |
|
|
1,233 |
|
Share-based compensation expense |
$ |
4,126 |
|
|
$ |
2,078 |
|
Share-based compensation expense by type of share-based award:
|
|
|
|
|
|
|
|
|
|
|
|
|
Years Ended December 31, |
|
(in thousands) |
|
2022 |
|
2021 |
Stock options |
$ |
1,076 |
|
|
$ |
686 |
|
RSAs and RSUs |
2,828 |
|
|
1,314 |
|
ESPP |
222 |
|
|
78 |
|
|
$ |
4,126 |
|
|
$ |
2,078 |
|
|
|
|
|
Total unrecognized compensation expense by type of award and the weighted-average remaining requisite service period over which such expense is expected to be recognized (in thousands, unless otherwise noted):
|
|
|
|
|
|
|
|
|
|
|
|
|
December 31, 2022 |
|
Unrecognized Expense |
|
Remaining Weighted-Average Recognition Period (in years) |
Stock options |
1,306 |
|
|
1.87 |
RSAs and RSUs |
5,649 |
|
|
2.13 |
|
Summary of Stock Option Activity |
Stock option activity under all of the Company’s Plans as of and for the year ended December 31, 2022 is summarized below:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Stock Options |
|
Weighted-average Exercise price per share |
|
Weighted-average Remaining Contractual Life (in years) |
|
Intrinsic Value (in thousands)(1)
|
Outstanding at December 31, 2021 |
1,350,473 |
|
|
$ |
10.10 |
|
|
|
|
|
Granted |
147,723 |
|
|
$ |
10.91 |
|
|
|
|
|
Exercised |
(30,000) |
|
|
$ |
2.45 |
|
|
|
|
|
Forfeited or expired |
(69,910) |
|
|
$ |
43.27 |
|
|
|
|
|
Outstanding at December 31, 2022 |
1,398,286 |
|
|
$ |
8.69 |
|
|
6.11 |
|
$ |
5,328 |
|
Exercisable at December 31, 2022 |
1,133,621 |
|
|
$ |
8.12 |
|
|
5.47 |
|
$ |
5,113 |
|
Vested and expected to vest at December 31, 2022 |
1,398,286 |
|
$ |
8.69 |
|
|
6.11 |
|
$ |
5,328 |
|
(1) Intrinsic value is calculated as the estimated fair value of the Company’s stock at December 31, 2022 less the option exercise price of in-the-money options.
|
Summary of Non-vested Stock Options |
A summary of the status of the Company’s non-vested stock options for the year ended December 31, 2022 is presented below:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Non-vested Stock Options |
|
Weighted - Average Grant Date Fair Value |
Nonvested, December 31, 2021 |
|
291,220 |
|
|
$ |
5.38 |
|
Granted |
|
147,723 |
|
|
$ |
8.21 |
|
Vested |
|
(169,987) |
|
|
$ |
5.16 |
|
Forfeited or expired |
|
(4,291) |
|
|
$ |
10.33 |
|
Nonvested, December 31, 2022 |
|
264,665 |
|
|
$ |
7.19 |
|
|
Summary of Fair Value Assumptions |
The fair value of each stock option is estimated on the date of grant using the Black-Scholes valuation model utilizing the following weighted average assumptions for options granted during the years ended December 31, 2022 and 2021:
|
|
|
|
|
|
|
|
|
|
|
|
|
Years Ended December 31, |
|
2022 |
|
2021 |
Risk-free interest rate |
3.07% |
|
0.95% |
Expected life (in years) |
5.93 |
|
5.86 |
Estimated volatility |
90.02% |
|
57.20% |
Expected dividends |
None |
|
None |
Weighted-average grant date fair value |
$8.21 |
|
$9.48 |
The fair value of the purchase options under the Purchase Plan are estimated at the beginning of the purchase period using the Black-Scholes valuation model utilizing the following assumptions:
|
|
|
|
|
|
|
|
|
|
|
|
|
2022 |
|
2021 |
Risk-free interest rate |
0.22% - 2.52% |
|
0.05% |
Expected life (in years) |
0.5 |
|
0.5 |
Estimated volatility |
61.29% - 78.23% |
|
57.82% |
Expected dividends |
None |
|
None |
Fair value of purchase right |
$4.14 |
|
$5.78 |
|
Summary of Restricted Stock Awards Activity |
RSA and RSU activity as of and for the year ended December 31, 2022 is summarized below:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Restricted Stock Award |
|
Weighted - Average Grant Date Fair Value |
Outstanding, December 31, 2021 |
|
380,105 |
|
|
$ |
10.41 |
|
Granted |
|
527,726 |
|
|
$ |
10.97 |
|
Vested |
|
(180,505) |
|
|
$ |
13.09 |
|
Forfeited or expired |
|
(29,791) |
|
|
$ |
14.22 |
|
Outstanding, December 31, 2022 |
|
697,535 |
|
|
$ |
11.11 |
|
|
Summary of Common Stock Warrant Activity |
Common stock warrant activity for the year ended December 31, 2022 is as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
Shares |
|
Weighted - Average Exercise Price |
Outstanding at December 31, 2021 |
668,907 |
|
|
$ |
2.97 |
|
Exercised |
(462,353) |
|
|
$ |
2.20 |
|
Terminated |
(170,000) |
|
|
$ |
2.20 |
|
Outstanding at December 31, 2022 |
36,554 |
|
|
$ |
16.23 |
|
Information regarding outstanding warrants at December 31, 2022 is as follows (contractual life expressed in years):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Exercise Price |
|
Number Outstanding |
|
Weighted-Average Remaining Contractual Life |
|
Intrinsic Value (in thousands)(1)
|
$16.23 |
|
36,554 |
|
|
0.46 |
|
— |
|
(1) Intrinsic value is calculated as the estimated fair value of the Company’s stock at December 31, 2022 less the warrant exercise price of in-the-money warrants.
|